Windlas Biotech Gets CDSCO Panel Nod To study Bisoprolol Fumarate, Telmisartan, Chlorthalidone FDC

Telmisartan is in a class of medications called angiotensin II receptor antagonists. It works by blocking the action of certain natural substances that tighten the blood vessels, allowing the blood to flow more smoothly and the heart to pump more efficiently.

Telmisartan is used alone or in combination with other medications to treat high blood pressure. Telmisartan is also used to decrease the chance of heart attack, stroke, or death in people 55 years of age or older who are at high risk for cardiovascular disease

Chlorthalidone is in the sulfamoylbenzamide class. As it lacks the benzothiadiazine structure of the thiazide-type diuretics, it is called a thiazide-like diuretic. Chlorthalidone is a diuretic medication that treats high blood pressure. It also treats swelling caused by heart, kidney, or liver disease. It works by helping your kidneys remove fluid and salt from your blood through your pee.

At the recent SEC meeting for Cardiovascular held on 5th March 2025, the expert panel reviewed the proposal along with the amended BE protocol.

After detailed deliberation, the committee recommended granting permission to conduct the BE study as per the presented amended BE protocol.

Accordingly, the expert panel suggested that the firm should submit a BE study report along with a Phase-III CT protocol to CDSCO for further review by the committee.

Also Read:Pfizer Gets CDSCO Panel Nod To Study Anticancer Drug Disitamab vedotin